ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

KNSA Kiniksa Pharmaceuticals Ltd

18.72
0.17 (0.92%)
Última actualización: 14:53:55
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Kiniksa Pharmaceuticals Ltd KNSA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.17 0.92% 18.72 14:53:55
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
18.49 18.2598 18.84 18.55
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
23/4/202406:30GLOBEKiniksa Pharmaceuticals Reports First Quarter 2024 Financial..
16/4/202415:01GLOBEKiniksa Pharmaceuticals to Report First Quarter 2024..
02/4/202406:30GLOBEKiniksa Pharmaceuticals Announces Development Indication for..
05/3/202415:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202415:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202416:29EDGAR2Form 144 - Report of proposed sale of securities
29/2/202415:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202406:35EDGAR2Form 8-K - Current report
28/2/202406:30GLOBEKiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year..
27/2/202416:06EDGAR2Form 144 - Report of proposed sale of securities
21/2/202415:01GLOBEKiniksa Pharmaceuticals to Report Fourth Quarter and..
14/2/202415:39EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202414:46EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
04/1/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202406:37EDGAR2Form 8-K - Current report
04/1/202406:30GLOBEKiniksa Pharmaceuticals Provides Corporate Update
03/1/202415:55EDGAR2Form 144 - Report of proposed sale of securities
02/1/202415:01GLOBEKiniksa Pharmaceuticals to Present at 42nd Annual J.P...
11/12/202315:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/12/202315:46EDGAR2Form 144 - Report of proposed sale of securities
02/11/202315:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/10/202306:35EDGAR2Form 8-K - Current report
31/10/202306:30GLOBEKiniksa Pharmaceuticals Reports Third Quarter 2023 Financial..
24/10/202315:01GLOBEKiniksa Pharmaceuticals to Report Third Quarter 2023..
06/9/202318:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202318:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202318:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202318:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202316:26EDGAR2Form 144 - Report of proposed sale of securities
18/8/202315:32EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
10/8/202315:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
01/8/202315:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
27/7/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/7/202316:14EDGAR2Form 144 - Report of proposed sale of securities
25/7/202306:40EDGAR2Form 8-K - Current report
25/7/202306:30GLOBEKiniksa Pharmaceuticals Reports Second Quarter 2023..
17/7/202307:00GLOBEKiniksa Pharmaceuticals to Report Second Quarter 2023..
06/6/202315:01GLOBEKiniksa Pharmaceuticals to Present at Goldman Sachs 44th..
02/5/202306:30GLOBEKiniksa Pharmaceuticals Reports First Quarter 2023 Financial..
01/5/202315:01GLOBEKiniksa Pharmaceuticals to Report First Quarter 2023..

Su Consulta Reciente

Delayed Upgrade Clock